Epidemiology, etiology, and diagnosis of health care acquired pneumonia including ventilator-associated pneumonia in Nepal

Epidemiologic data regarding health care acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) from Nepal are negligible. We conducted a prospective observational cohort study in the intensive care unit (ICU) of a major tertiary hospital in Nepal between April 2016 and March 2018, to calculate the incidence of VAP, and to describe clinical variables, microbiological etiology, and outcomes. Four hundred and thirty-eight patients were enrolled in the study. Demographic data, medical history, antimicrobial administration record, chest X-ray, biochemical, microbiological and haematological results, acute physiology and chronic health evaluation II score and the sequential organ failure assessment scores were recorded. Categorical variables were expressed as count and percentage and analyzed using the Fisher’s exact test. Continuous variables were expressed as median and interquartile range and analyzed using Kruskal-Wallis rank sum test and the pairwise Wilcoxon rank—sum test. 46.8% (205/438) of the patients required intubation. Pneumonia was common in both intubated (94.14%; 193/205) and non-intubated (52.36%; 122/233) patients. Pneumonia developed among intubated patients in the ICU had longer days of stay in the ICU (median of 10, IQR 5–15, P< 0.001) when compared to non-intubated patients with pneumonia (median of 4, IQR 3–6, P< 0.001). The incidence rate of VAP was 20% (41/205) and incidence density was 16.45 cases per 1,000ventilator days. Mortality was significantly higher in patients with pneumonia requiring intubation (44.6%, 86/193) than patients with pneumonia not requiring intubation (10.7%, 13/122, p<0.001, Fisher’s exact test). Gram negative bacteria such as Klebsiella and Acinetobacter species were the dominant organisms from both VAP and non-VAP categories. Multi-drug resistance was highly prevalent in bacterial isolates associated with VAP (90%; 99/110) and non-VAP categories (81.5%; 106/130). HAP including VAP remains to be the most prevalent hospital-acquired infections (HAIs) at Patan hospital. A local study of etiological agents and outcomes of HAP and VAP are required for setting more appropriate guidelines for management of such diseases.

[1]  M. Klompas,et al.  Ventilator-associated pneumonia in adults: a narrative review , 2020, Intensive Care Medicine.

[2]  Guogang Xu,et al.  Risk factors of ventilator-associated pneumonia in elderly patients receiving mechanical ventilation , 2019, Clinical interventions in aging.

[3]  Tiantuo Zhang,et al.  Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou , 2019, Infection and drug resistance.

[4]  S. Lewycka,et al.  A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and Etiology , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Wunderink,et al.  Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia , 2018, ERJ Open Research.

[6]  H. Wertheim,et al.  Ventilator-associated respiratory infection in a resource-restricted setting: impact and etiology , 2017, Journal of Intensive Care.

[7]  J. Timsit,et al.  Update on ventilator-associated pneumonia , 2017, F1000Research.

[8]  L. Bouadma,et al.  Hospital-acquired pneumonia in ICU. , 2017, Anaesthesia, critical care & pain medicine.

[9]  K. Giuliano,et al.  The epidemiology of nonventilator hospital‐acquired pneumonia in the United States , 2017, American journal of infection control.

[10]  R. Wunderink,et al.  International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia , 2017, European Respiratory Journal.

[11]  V. Patil,et al.  Incidence, bacteriology, and clinical outcome of ventilator-associated pneumonia at tertiary care hospital , 2017, Journal of natural science, biology, and medicine.

[12]  C. Thomson,et al.  Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia. , 2016, Annals of the American Thoracic Society.

[13]  A. Mathai,et al.  Ventilator-associated pneumonia: A persistent healthcare problem in Indian Intensive Care Units! , 2016, Lung India : official organ of Indian Chest Society.

[14]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Baker,et al.  In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam , 2015, Journal of medical microbiology.

[16]  Adriano Menis Ferreira,et al.  Colheita de aspirado traqueal: segurança e concordância microbiológica entre duas técnicas , 2014 .

[17]  Marek Mirski,et al.  Ventilator-associated pneumonia in the ICU , 2014, Critical Care.

[18]  S. Joshi,et al.  Acinetobacter baumannii: An emerging pathogenic threat to public health , 2013 .

[19]  Rolf H H Groenwold,et al.  Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. , 2013, The Lancet. Infectious diseases.

[20]  J. Sherchand,et al.  Fact-finding Survey of Nosocomial Infection Control in Hospitals in Kathmandu, Nepal—A Basis for Improvement , 2013, Tropical medicine and health.

[21]  S. Ranjit,et al.  Incidence and risk factor for ventilator-associated pneumonia in Kathmandu University Hospital. , 2012, Kathmandu University medical journal.

[22]  A. Barkat,et al.  Findings of the International Nosocomial Infection Control Consortium (INICC), Part II: Impact of a Multidimensional Strategy to Reduce Ventilator-Associated Pneumonia in Neonatal Intensive Care Units in 10 Developing Countries , 2012, Infection Control &#x0026; Hospital Epidemiology.

[23]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[24]  Richard Platt,et al.  Rapid and reproducible surveillance for ventilator-associated pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. Welte,et al.  Clinical and economic burden of community-acquired pneumonia among adults in Europe , 2010, Thorax.

[26]  Jordi Rello,et al.  International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.

[27]  古谷 良輔,et al.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.

[28]  R. Chawla Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. , 2008, American journal of infection control.

[29]  V. Rosenthal,et al.  Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC). , 2007, The Journal of hospital infection.

[30]  Roger Resar,et al.  Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. , 2005, Joint Commission journal on quality and patient safety.

[31]  Marin H Kollef,et al.  Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.

[32]  A. Torres,et al.  The pulmonary physician in critical care • 4: Nosocomial pneumonia , 2002, Thorax.

[33]  M. Niederman,et al.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. , 1997, Chest.

[34]  G. D. Thomas,et al.  Nosocomial respiratory infections with gram-negative bacilli. The significance of colonization of the respiratory tract. , 1972, Annals of internal medicine.

[35]  Athavudh Deesomchok,et al.  Ventilator-associated pneumonia: epidemiology and prognostic indicators of 30-day mortality. , 2015, Japanese journal of infectious diseases.

[36]  G. Dimopoulos,et al.  Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. , 2014, International journal of antimicrobial agents.

[37]  P. Kiratisin,et al.  Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. , 2010, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[38]  谷口博之,et al.  急性肺損傷のstate of the art 人工呼吸器関連肺炎(ventilator associated pneumonia:VAP)の診断と治療 , 2002 .